PGT Appoints New VP of Business Development
May 25, 2009
Population Genetics Technologies (PGT) Ltd today announced the appointment of Dr Frank Massam as Vice President of Business Development. The move follows the recent announcement of a £2,000,000 second tranche of Series A funding to further develop and commercialize PGT’s suite of proprietary technologies.
Massam has previously held senior Business Development positions with Incyte Genomics, Pharmagene Ltd and was responsible for Strategic Planning and New Business Development at Agilent Technologies Inc.
Commenting on the appointment Massam said, “I am delighted to be joining PGT at this most exciting time of its development. The technologies and the team that PGT has been able to put together in a short space of time are truly outstanding and I believe the company’s impact on discovery, diagnostic and research workflows will be significant. I am looking forward very much to helping plot the commercial course of the company as it introduces and enables economical, large-scale population studies allowing the detection and characterization of rare allelic variants”
Mel Kronick, President and CEO of PGT added, “We were recently able to secure the second tranche of our Series A funding by proving the feasibility, scalability and applicability of our proprietary technologies. The next phase of our growth will include pre-commercial assessments of potential markets, applications, business models and partners. The PGT Board and I are delighted to welcome Frank to the PGT team since he is a proven resource with a very strong track record of success in our industry. We look forward to working with him to bring the benefits of our research to the market.”